Mymetics Corp. (OTC: MYMX) is a Switzerland-based biotechnology company focused on the development of next-generation preventative vaccines for infectious diseases. The company’s vaccines are designed to induce protection against early transmission and infection. They focus on the mucosal immune response as a first line of defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Mymetics currently has five vaccines in its pipeline for HIV-1/AIDS, intra-nasal influenza, malaria, herpes simplex virus and the RSV vaccine. For more information, visit the company’s website at www.mymetics.com.